# Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Kidney Transplantation.

> **NCT01939977** · PHASE4 · COMPLETED · sponsor: **Fundación Senefro** · enrollment: 148 (actual)

## Conditions studied

- Secondary Hyperparathyroidism Due to Renal Causes

## Interventions

- **DRUG:** Paricalcitol
- **DRUG:** Calcifediol

## Key facts

- **NCT ID:** NCT01939977
- **Lead sponsor:** Fundación Senefro
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2015-09
- **Final completion:** 2015-12
- **Target enrollment:** 148 (ACTUAL)
- **Last updated:** 2018-11-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01939977

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01939977, "Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Kidney Transplantation.". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01939977. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*